Based on the analysis of AnaptysBio's profitability, liquidity, and operating efficiency, AnaptysBio may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At present, AnaptysBio's Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Property Plant And Equipment Net is expected to grow to about 19.2 M, whereas Total Assets are forecasted to decline to about 354.3 M. Key indicators impacting AnaptysBio's financial strength include:
Investors should never underestimate AnaptysBio's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor AnaptysBio's cash flow, debt, and profitability to make informed and accurate decisions about investing in AnaptysBio.
Net Income
(155.44 Million)
AnaptysBio
Select Account or Indicator
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change To Inventory
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Sale Purchase Of Stock
Investments
Net Borrowings
Total Cashflows From Investing Activities
Change To Operating Activities
Other Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Issuance Of Capital Stock
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Current Deferred Revenue
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Common Stock Total Equity
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Short Term Debt
Common Stock
Other Liab
Net Tangible Assets
Other Assets
Long Term Debt
Net Receivables
Short Long Term Debt
Property Plant Equipment
Long Term Debt Total
Capital Surpluse
Retained Earnings Total Equity
Short Term Investments
Capital Lease Obligations
Net Invested Capital
Long Term Investments
Non Current Liabilities Other
Net Working Capital
Depreciation And Amortization
Interest Expense
Selling General Administrative
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Net Income From Continuing Ops
Cost Of Revenue
Net Income Applicable To Common Shares
Tax Provision
Interest Income
Net Interest Income
Reconciled Depreciation
Non Operating Income Net Other
Probability Of Bankruptcy
Understanding current and past AnaptysBio Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of AnaptysBio's financial statements are interrelated, with each one affecting the others. For example, an increase in AnaptysBio's assets may result in an increase in income on the income statement.
Please note, the presentation of AnaptysBio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, AnaptysBio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of AnaptysBio's management manipulating its earnings.
AnaptysBio Stock Summary
AnaptysBio competes with Crinetics Pharmaceuticals, Rhythm Pharmaceuticals, Kura Oncology, and CytomX Therapeutics. AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California. Anaptysbio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 102 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
AnaptysBio's financial ratios allow both analysts and investors to convert raw data from AnaptysBio's financial statements into concise, actionable information that can be used to evaluate the performance of AnaptysBio over time and compare it to other companies across industries.
Comparative valuation techniques use various fundamental indicators to help in determining AnaptysBio's current stock value. Our valuation model uses many indicators to compare AnaptysBio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across AnaptysBio competition to find correlations between indicators driving AnaptysBio's intrinsic value. More Info.
AnaptysBio is rated fifth in return on equity category among its peers. It is rated second in return on asset category among its peers . At present, AnaptysBio's Return On Equity is projected to increase significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the AnaptysBio's earnings, one of the primary drivers of an investment's value.
AnaptysBio Systematic Risk
AnaptysBio's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. AnaptysBio volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fifty with a total number of output elements of eleven. The Beta measures systematic risk based on how returns on AnaptysBio correlated with the market. If Beta is less than 0 AnaptysBio generally moves in the opposite direction as compared to the market. If AnaptysBio Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one AnaptysBio is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of AnaptysBio is generally in the same direction as the market. If Beta > 1 AnaptysBio moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in AnaptysBio Stock are looking for potential investment opportunities by analyzing not only static indicators but also various AnaptysBio's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of AnaptysBio growth as a starting point in their analysis.
Price Earnings To Growth Ratio
(0.11)
At present, AnaptysBio's Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting.
AnaptysBio September 23, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of AnaptysBio help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of AnaptysBio. We use our internally-developed statistical techniques to arrive at the intrinsic value of AnaptysBio based on widely used predictive technical indicators. In general, we focus on analyzing AnaptysBio Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build AnaptysBio's daily price indicators and compare them against related drivers.
When running AnaptysBio's price analysis, check to measure AnaptysBio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AnaptysBio is operating at the current time. Most of AnaptysBio's value examination focuses on studying past and present price action to predict the probability of AnaptysBio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AnaptysBio's price. Additionally, you may evaluate how the addition of AnaptysBio to your portfolios can decrease your overall portfolio volatility.